Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Γαληνός Office Χρησιμοποιήστε δωρεάν το νέο cloud πρόγραμμα διαχείρισης κάθε σύγχρονου ιατρείου
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Πρόγραμμα συνδρομητών Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Γαληνός Mobile Κατεβάστε τη δωρεάν εφαρμογή και απολαύστε τις υπηρεσίες του Galinos.gr σε κινητό ή tablet
Γνωρίζατε οτι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα
®
 Περιεχόμενα  Φάρμακα Α - Ζ  Συγχορήγηση

THALIDOMIDE CELGENE Hard capsules (2019)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

Thalidomide Celgene 50 mg hard capsules.

Qualitative and quantitative composition

Each capsule contains 50 mg of thalidomide. For the full list of excipients, see section 6.1.

Pharmaceutical form

Hard capsule. White opaque capsules marked Thalidomide Celgene 50 mg.

Therapeutic indications

Thalidomide Celgene in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥65 years or ineligible for high dose chemotherapy. ...

Posology and method of administration

Treatment must be initiated and monitored under the supervision of physicians with expertise in managing immunomodulatory or chemotherapeutic agents and a full understanding of the risks of thalidomide ...

Contraindications

Hypersensitivity to thalidomide or to any of the excipients listed in section 6.1. Women who are pregnant (see section 4.6). Women of childbearing potential unless all the conditions of the Pregnancy Prevention ...

Special warnings and precautions for use

Teratogenic effects Thalidomide is a powerful human teratogen, inducing a high frequency of severe and life-threatening birth defects. Thalidomide must never be used by women who are pregnant or by women ...

Interaction with other medicinal products and other forms of interaction

Thalidomide is a poor substrate for cytochrome P450 isoenzymes and therefore clinically important interactions with medicinal products that are inhibitors and/or inducers of this enzyme system are unlikely. ...

Fertility, pregnancy and lactation

Women of childbearing potential/Contraception in males and females Women of childbearing potential must use one effective method of contraception for at least 4 weeks before start of treatment, during ...

Effects on ability to drive and use machines

Thalidomide Celgene as per the recommended posology has minor or moderate influence on the ability to drive and use machines. Thalidomide may cause fatigue (very common), dizziness (very common), somnolence ...

Undesirable effects

Summary of the safety profile Most patients taking thalidomide can be expected to experience adverse reactions. The most commonly observed adverse reactions associated with the use of thalidomide in combination ...

Overdose

Eighteen cases of overdose have been reported in the literature concerning doses up to 14.4 grams. In thirteen of these cases, patients took thalidomide alone; amounts ranged from 350 mg to 4000 mg. These ...

Pharmacodynamic properties

Pharmacotherapeutic group: immunosuppressants, other immunosuppressants ATC code: L04AX02 Thalidomide has a chiral centre and is used clinically as a racemate of (+) - (R) and (-) - (S)-thalidomide. The ...

Pharmacokinetic properties

Absorption Absorption of thalidomide is slow after oral administration. The maximum plasma concentrations are reached 1-5 hours after administration. Co-administration of food delayed absorption but did ...

Preclinical safety data

In the male dog, after one year of dosing, reversible bile plugs in canaliculi were observed at exposures greater than 1.9-fold the human exposure. Decreased platelet counts were noted in the mouse and ...

List of excipients

Capsule contents: Starch, pregelatinised Magnesium stearate Capsule shell: Gelatin Titanium dioxide (E171) Printing ink: Shellac Black iron oxide (E172) Propylene glycol

Incompatibilities

Not applicable.

Shelf life

5 years.

Special precautions for storage

This medicinal product does not require any special storage conditions.

Nature and contents of container

PVC/PCTFE/aluminium blister containing 14 capsules. Pack sizes: 28 capsules (two blisters) in a wallet card.

Special precautions for disposal and other handling

Capsules should not be opened or crushed. If powder from thalidomide makes contact with the skin, the skin should be washed immediately and thoroughly with soap and water. If thalidomide makes contact ...

Marketing authorization holder

Celgene Europe B.V., Winthontlaan 6 N, 3526 KV Utrecht, Netherlands

Marketing authorization number(s)

EU/1/08/443/001

Date of first authorization / renewal of the authorization

Date of first authorisation: 16 April 2008 Date of latest renewal: 08 February 2018

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: